<?xml version="1.0" encoding="UTF-8"?>
<p>Human immunodeficiency virus primarily targets the immune system, including CD4
 <sup>+</sup> T cells and macrophages. After sexual transmission, HIV enters into CD4
 <sup>+</sup> cells in the mucosal tissues and then spreads to the lymphoid organs within days (
 <xref rid="B68" ref-type="bibr">Haase, 2005</xref>; 
 <xref rid="B105" ref-type="bibr">Moir et al., 2011</xref>). The immune system of the HIV-infected patient is gradually destroyed, eventually resulting in acquired immunodeficiency syndrome (AIDS) and death (
 <xref rid="B105" ref-type="bibr">Moir et al., 2011</xref>). More than 40 anti-HIV drugs have been approved by the United States FDA, most of which are reverse transcriptase inhibitors (RTIs, including NRTIs and NNRTIs), protease inhibitors (PIs) and integrase inhibitors (INIs) (
 <xref rid="B46" ref-type="bibr">Deeks et al., 2015</xref>). They must enter HIV-infected cells to inhibit viral replication. The only peptide-based HIV fusion inhibitor, enfuvirtide (also known as T20) (
 <xref rid="B82" ref-type="bibr">Jiang et al., 1993a</xref>; 
 <xref rid="B154" ref-type="bibr">Wild et al., 1994</xref>; 
 <xref rid="B91" ref-type="bibr">Lalezari et al., 2003</xref>), and a small-molecule CCR5 antagonist, maraviroc (
 <xref rid="B59" ref-type="bibr">Fatkenheuer et al., 2005</xref>), must act on the cell surface where the virus binds to the cellular receptor (
 <xref rid="B99" ref-type="bibr">Lu et al., 2016</xref>). These drugs have shown good effects in combating HIV; however, they cannot attack the cell-free virions in the blood, thus also having the problem of low utilization rate.
</p>
